New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2012
12:22 EDTXOM, LEAP, BCO, SWI, PCS, ALU, AKAM, AET, PHM, REGN, XLNX, EQIX, CTXS, CHK, JNJ, UPS, NIHDOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, in spite of jobless claims that were higher than expected and disappointing results from Exxon Mobil (XOM). Stocks began the day quietly following the jobless claims data. The averages were mixed in the opening half hour but spurted higher following the March pending home sales report. The data was much better than expected and pushed the averages to their session highs. The averages have since remained in a narrow range but have drifted higher... ECONOMIC EVENTS: Domestically, 388,000 initial jobless claims were reported, versus expectations of 375,000. Continuing claims came in at 3.31M, versus expectations for 3.29M. The Chicago Fed National Activity Index had a reading of -0.29. Pending home sales for the month of March were up 4.1% from the prior month, versus expectations of an increase of 1.0%... COMPANY NEWS: Exxon Mobil and UPS (UPS) both reported revenues and earnings that missed expectations, sending shares of both tumbling. Exxon slid almost 2% following its report, while UPS fell over 3%... Johnson & Johnson (JNJ) increased its dividend by 7%... Reuters reported that the SEC opened an informal inquiry into Chesapeake Energy's (CHK) well participation program as the company came out separately and said it did not review or approve of specific transactions made by its CEO Aubrey McClendon under that program... Among companies reporting earnings, advancers included Citrix Systems (CTXS), Equinix (EQIX), Xilinx (XLNX), Regeneron (REGN) and Pulte (PHM); decliners included Aetna (AET), Akamai (AKAM), Alcatel-Lucent (ALU) and MetroPCS (PCS)... MAJOR MOVERS: Among the notable gainers were SolarWinds (SWI), up 19%, after guiding to FY12 adjusted earnings that were above consensus at the midpoint, and Brinks (BCO), up over 17%, following results that beat on both the top and bottom line. Noteworthy losers included Leap Wireless (LEAP), down 20%, following downgrades at Raymond James and Guggenheim after its weak Q1 results, and NII Holdings (NIHD), down more than 18%, after its revenues and earnings disappointed... INDICES: Near noon, the Dow was up 63.46, or 0.48%, to 13,154.18; the Nasdaq was up 6.61, or 0.22%, to 3,036.24; and the S&P 500 was up 2.62, or 0.19%, to 1,393.31.
News For XOM;UPS;JNJ;CHK;CTXS;EQIX;XLNX;REGN;PHM;AET;AKAM;ALU;PCS;SWI;BCO;LEAP;NIHD From The Last 14 Days
Check below for free stories on XOM;UPS;JNJ;CHK;CTXS;EQIX;XLNX;REGN;PHM;AET;AKAM;ALU;PCS;SWI;BCO;LEAP;NIHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 15, 2014
10:05 EDTJNJJohnson & Johnson says committed to diabetes space
Subscribe for More Information
09:50 EDTJNJJohnson & Johnson sees competition in Hepatitis products a headwind in 2015
Subscribe for More Information
09:36 EDTJNJJohnson & Johnson sees FY14 pre-tax op. margin improving over FY13
Subscribe for More Information
09:30 EDTJNJJohnson & Johnson says will buy back shares with net gain from OCD divestiture
Subscribe for More Information
09:28 EDTJNJJohnson & Johnson sees 2014 sales $74.5B-$75.3B, consensus $74.91B
Subscribe for More Information
08:54 EDTJNJJ&J CEO says confident about long term growth prospects of healthcare market
Subscribe for More Information
08:37 EDTEQIXEquinix and NetApp expand cloud partnership
Equinix (EQIX), and NetApp (NTAP) announced that they are expanding their cloud partnership. The two companies now provide an expanded offering of private storage solutions for the public cloud including NetApp Private Storage for Microsoft Azure, through the Equinix Cloud Exchange, which makes connecting to the cloud simple and convenient.
08:25 EDTJNJJohnson & Johnson says innovation sustaining long-term growth
Says MD&D progressing well towards 30 major filings by 2017. In Pharmaceuticals, sees 10 new products and 25 significant line extensions planned by 2017. Sees ~4.5% CAGR expected for WW prescription drug sales through 2017, despite potential headwinds. Comments from slides that will be presented on the Q2 earnings conference call.
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
July 14, 2014
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
10:59 EDTCTXSElliot reaffirms $21 Riverbed bid following Q2 warning
Subscribe for More Information
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
07:04 EDTCHKExterran Partners to acquire natural gas compression assets from MidCon
Subscribe for More Information
July 11, 2014
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use